Edition:
United Kingdom

Aceto Corp (ACET.OQ)

ACET.OQ on NASDAQ Stock Exchange Global Select Market

0.17USD
22 Mar 2019
Change (% chg)

$-0.00 (-0.64%)
Prev Close
$0.17
Open
$0.17
Day's High
$0.18
Day's Low
$0.16
Volume
387,919
Avg. Vol
549,352
52-wk High
$7.64
52-wk Low
$0.14

Latest Key Developments (Source: Significant Developments)

ACETO Enters into “Stalking Horse” Agreement to Sell Rising Pharmaceuticals
Friday, 8 Mar 2019 

March 7 (Reuters) - Aceto Corp ::PRESS RELEASE - ACETO ENTERS INTO “STALKING HORSE” AGREEMENT TO SELL RISING PHARMACEUTICALS.ACETO - "STALKING-HORSE" ASSET PURCHASE AGREEMENT WITH SHORE SUVEN PHARMATO SELL ASSETS OF RISING PHARMACEUTICALS, RISING'S SUBSIDIARIES FOR $15 MILLION.PROPOSED SALE WILL BE CONDUCTED THROUGH A COURT-SUPERVISED PROCESS UNDER SECTION 363 OF BANKRUPTCY CODE.  Full Article

Aceto Announces Proposed Sale Of Its Chemicals Business Assets To New Mountain Capital For $338 Mln
Wednesday, 20 Feb 2019 

Feb 19 (Reuters) - Aceto Corp ::ACETO ANNOUNCES PROPOSED SALE OF ITS CHEMICALS BUSINESS ASSETS TO NEW MOUNTAIN CAPITAL FOR $338 MILLION.SECURES COMMITMENT FOR DEBTOR-IN-POSSESSION FINANCING TO SUPPORT NORMAL COURSE OPERATIONS.ACETO AND ITS U.S. SUBSIDIARIES FILE VOLUNTARY CHAPTER 11 PETITIONS TO FACILITATE SALE.ACETO PURSUING COURT-SUPERVISED SALE OF RISING PHARMACEUTICALS.CO RECEIVED COMMITMENT FOR DEBTOR-IN-POSSESSION (DIP) FINANCING OF $60 MILLION FROM A SYNDICATE OF LENDERS LED BY WELLS FARGO BANK, N.A.ACETO - WILL OPERATE ITS BUSINESS IN ORDINARY COURSE WHILE IT COMPLETES THE SALES OF CHEMICALS BUSINESS ASSETS & ITS SUBSIDIARY RISING PHARMACEUTICALS.ACETO - ACETO'S FOREIGN CHEMICALS BUSINESS SUBSIDIARIES ARE NOT INCLUDED IN THE FILING BUT WILL BE INCLUDED IN THE SALE.ENTERED INTO "STALKING-HORSE" ASSET PURCHASE AGREEMENT WITH AFFILIATE OF NEW MOUNTAIN CAPITAL TO SELL ITS CHEMICALS BUSINESS ASSETS.ACETO - ACETO EXPECTS TO COMPLETE THE DISPOSITIONS OF ITS CHEMICALS AND RISING BUSINESSES BEFORE ITS FISCAL YEAR END ON JUNE 30, 2019.  Full Article

Aceto Says On Jan 8, Amended Its Existing Senior Secured Credit Agreement
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Aceto Corp ::ACETO SAYS ON JAN 8, AMENDED ITS EXISTING SENIOR SECURED CREDIT AGREEMENT - SEC FILING.ACETO CORP - AMENDMENT ALLOW CO TO RESUME ACCESS TO UP TO $23.0 MILLION OF ITS REVOLVING CREDIT FACILITY.ACETO CORP - FURTHER COMPLIANCE WITH MINIMUM LIQUIDITY COVENANT FROM THIRD AMENDMENT TO CREDIT AGREEMENT HAS BEEN PERMANENTLY WAIVED.ACETO CORP - JANUARY AMENDMENT ALSO REVISES BOTH REVOLVING LOAN MATURITY DATE AND TERM LOAN MATURITY DATE TO JUNE 30, 2019.  Full Article

Aceto Reports Q1 Loss Per Share Of $0.59
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Aceto Corp ::ACETO REPORTS FISCAL 2019 FIRST QUARTER RESULTS.Q1 LOSS PER SHARE $0.59.Q1 SALES FELL 11.3 PERCENT TO $164.4 MILLION.CO HAS SUSPENDED GIVING FINANCIAL GUIDANCE DURING ONGOING STRATEGIC REVIEW PERIOD.  Full Article

Aceto Corp Files For Non-Timely 10-K With U.S. SEC
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Aceto Corp ::ACETO CORP FILES FOR NON-TIMELY 10-K WITH U.S. SEC.ACETO CORP SAYS HAS ENCOUNTERED A DELAY IN COMPLETING THE FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED JUNE 30, 2018.ACETO - TO SEE WHETHER TO RECORD ADDITIONAL VALUATION ALLOWANCE IN FISCAL YEAR ENDED JUNE 30 REGARDING SOME/ALL OF $76.5 MILLION DOMESTIC NET DEFERRED TAX ASSETS.  Full Article

Aceto Subsidiary Acetris Health Receives Favorable Ruling Regarding Certain Government Contracts
Monday, 16 Jul 2018 

July 16 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY ACETRIS HEALTH RECEIVES FAVORABLE RULING REGARDING CERTAIN GOVERNMENT CONTRACTS.ACETO- COURT DECISION IN ACETRIS HEALTH LLC V. UNITED STATES, INVALIDATING U.S. DEPARTMENT OF VETERANS AFFAIRS INTERPRETATION OF TRADE AGREEMENTS CLAUSE.ACETO CORP - DECISION ALSO IMPACTS ACETRIS' ABILITY TO SUPPLY DOD WITH ITS PRODUCTS.  Full Article

Aceto-With DOJ’S Ongoing Investigation In Marketing, Pricing Practices In Generic Pharma Industry, Co Got Subpoena From U.S. DOJ Antitrust Division
Monday, 23 Apr 2018 

April 23 (Reuters) - Aceto Corp ::ACETO-WITH DOJ’S ONGOING INVESTIGATION IN MARKETING, PRICING PRACTICES IN GENERIC PHARMACEUTICAL INDUSTRY, CO GOT SUBPOENA FROM U.S. DOJ ANTITRUST DIVISION.ACETO CORP SAYS COMPANY IS CURRENTLY PREPARING ITS RESPONSE TO THE SUBPOENA - SEC FILING.  Full Article

Aceto Subsidiary, Rising Pharmaceuticals, Launches Atenolol Tablets, 25Mg, 50Mg And 100Mg
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES ATENOLOL TABLETS, 25MG, 50MG AND 100MG.ACETO - UNIT LAUNCHED ATENOLOL TABLETS, 25MG, 50MG AND 100MG, GENERIC VERSION OF TENORMIN FROM ALVOGEN MALTA OPERATIONS.  Full Article

Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES EFAVIRENZ CAPSULES, 50MG AND 200MG.SAYS UNIT ‍LAUNCHED GENERIC FOR EFAVIRENZ CAPSULES, AN FDA-APPROVED GENERIC VERSION OF REFERENCE LISTED DRUG SUSTIVA FROM BRISTOL MYERS SQUIBB​.  Full Article

Aceto reports fiscal 2018 first quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Aceto Corp :Aceto reports fiscal 2018 first quarter results.Q1 adjusted non-GAAP earnings per share $0.30.Q1 earnings per share $0.01.Q1 sales $185.3 million versus I/B/E/S view $190.6 million.Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S.Sees FY 2018 non-GAAP earnings per share $1.05 to $1.15.Aceto Corp sees ‍fiscal 2018 total revenues to increase approximately 15% to 20%​.Aceto Corp sees ‍fiscal 2018 reported diluted GAAP earnings per share between $0.23 and $0.33​.  Full Article